CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP-R) ANTAGONIST
Ubrelvy is approved by the U.S. Food and Drug Administration (FDA) to prevent migraine in adults. Ubrelvy is also referred to by its drug name, Ubrogepant.
Ubrelvy is a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Ubrelvy is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.
How do I take it?
Ubrelvy is taken as needed, up to 200 mg a day.
Ubrelvy comes in tablet form.
The FDA-approved label for Ubrelvy lists common side effects including nausea and sleepiness.
Because Ubrelvy is a new drug, its long-term effects are not yet known.
For more details about this treatment, visit:
Ubrelvy – AbbVie
We never share your personal information with anyone.